Date: 2017-04-17
Type of information: Research agreement
Compound: characterization of immunologic profiles from advanced malignant tumor samples collected in the ProfiLER study
Company: HTG Molecular Diagnostics (US - AZ) Centre Léon Bérard (France)
Therapeutic area: Cancer - Oncology - Technology - Services
Type agreement: R&D - research
Action mechanism:
Disease:
Details: • On April 17, 2017, HTG Molecular Diagnostics, a provider of instruments, reagents, and services for molecular profiling applications, announced that it has entered into a research agreement with Centre Léon Bérard, which provides the framework for molecular profiling studies aimed to advance precision medicine. The initial project utilizes the HTG EdgeSeq Oncology Biomarker Panel to retrospectively characterize immunologic profiles from advanced malignant tumor samples collected in the ProfiLER study (NCT01774409). “We believe this immunogenic profiling of tumors, led by Dr. Pierre Saintigny within the Department of Translational Research and Innovation, will allow us to identify biomarkers with a potential predictive value and to determine if some genetic disorders are linked to immunity status alterations,” said Pr. Jean-Yves Blay, M.D., Ph.D., Director of Centre Léon Bérard.
Financial terms:
Latest news:
